Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study.

Autor: Ng T; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Lee YY; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Chae JW; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Yeo AHL; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Shwe M; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Gan YX; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore., Ng RCH; Duke-NUS Medical School Singapore, Singapore, Singapore.; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Chu PPY; Singapore Cord Blood Bank, K.K. Women's and Children's Hospital, Singapore, Singapore., Khor CC; Genome Institute of Singapore, Singapore, Singapore., Ho HK; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore., Chan A; Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. phaac@nus.edu.sg.; Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. phaac@nus.edu.sg.; Duke-NUS Medical School Singapore, Singapore, Singapore. phaac@nus.edu.sg.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2017 Dec 19; Vol. 17 (1), pp. 867. Date of Electronic Publication: 2017 Dec 19.
DOI: 10.1186/s12885-017-3861-9
Abstrakt: Background: Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI.
Methods: This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed using Sanger Sequencing.
Results: A total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 ± 9.5 years) were recruited, and 11 patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points among Met homozygous carriers (p = 0.107).
Conclusion: There was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy.
Databáze: MEDLINE
Externí odkaz: